RSS   Newsletter   Contact   Advertise with us
Post Online Media

AzurRx BioPharma appoints Vern Lee Schramm to board

AzurRx BioPharmaAzurRx BioPharma, a biopharmaceutical company, announced the appointment of Vern Lee Schramm to the board of directors.
Article continues below

READ MORE AzurRx BioPharma appoints Maged Shenouda as CFO

Dr. Schramm has served as Professor of the Albert Einstein College of Medicine since 1987.

Dr. Schramm served as the Chairman of the Department of Chemistry at the Albert Einstein College of Medicine from 1987 to 2015.

He has been awarded the Ruth Merns Endowed Chair of Biochemistry.

Dr. Schramm's fields of interest include enzymatic transition state analysis, transition state inhibitor design, biological targets for inhibitor design, and mechanisms of N-ribosyltransferases.

Dr. Schramm was elected to the National Academy of Sciences in 2007, and served as the Associate Editor for the Journal of the American Chemical Society from 2003 to 2012.

A frequent lecturer and presenter in topics related to chemical biology, Dr. Schramm has been a consultant and advisor to Pico Pharmaceuticals, Metabalon Biochemistry, Sirtris Scientific, and BioCryst Pharmaceuticals.

Dr. Schramm obtained his BS in Bacteriology with an emphasis in chemistry from South Dakota State College, a Master’s Degree in Nutrition with an emphasis in biochemistry from Harvard University, and a Ph.D. in Mechanism of Enzyme Action, Department of Biochemistry, from Australian National University.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy